Publications

These publications represent previous work supported in part by The Cancer Research Foundation:

Yang X, Lee Y, Fan H, Sun X, Lussier YA. Identification of common microRNA-mRNA regulatory biomodules in human epithelial cancers. Chinese Science Bulletin 55:3576-3589, 2010.

Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, and Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplantation. Leukemia Lymphoma 51:995-1006, 2010.

Godley LA, Larson RA. Therapy-related myeloid leukemia. Seminars in Oncol 35:418-429, 2008.

These publications are a direct result of the successful partnership between the University of Chicago Comprehensive Cancer Center and The Cancer Research Foundation to fight therapy-related leukemia:

Spooner CJ, Cheng JX, Pujadas E, Laslo P, Singh H. A recurrent network involving the transcription factors PU.1 and Gfi1 orchestrates innate and adaptive immune cell fates. Immunity 31:576-586, 2009.

Yang X, Huang Y, Chen J, Xie J, Sun X, Lussier YA. Mechanism-Anchored Profiling derived from Epigenetic Networks Predicts Outcome in Acute Lymphoblastic Leukemia. BMC Bioinformatics 10(Suppl 9):S6, 2009.

Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, and Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplantation. Leukemia Lymphoma 51:995-1006, 2010.

Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol 38:215-224, 2011.

Best T, Li D, Skol AD, Kirchhoff T, Jackson SA, Yasui Y, Bhatia S, Strong LC, Domchek SM, Nathanson KL, Olopade O, Mack TM, Conti DV, Offit K, Cozen W, Robison LL, Onel K.  Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin lymphoma. Nature Med [Epub ahead of print], 2011.

Check for future updates.